S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.57 (-1.00%)
MSFT   420.44 (-0.23%)
META   488.14 (-1.16%)
GOOGL   150.85 (-0.01%)
AMZN   180.48 (+0.36%)
TSLA   176.90 (-1.63%)
NVDA   904.14 (+0.18%)
NIO   4.54 (-2.78%)
AMD   180.75 (+0.65%)
BABA   72.50 (+1.27%)
T   17.66 (+0.63%)
F   13.23 (+1.30%)
MU   117.80 (-1.12%)
CGC   8.95 (-6.28%)
GE   174.91 (-2.89%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   27.96 (+0.65%)
PYPL   67.16 (+0.89%)
XOM   116.15 (+1.03%)
OTCMKTS:MKGAF

Merck KGaA (MKGAF) Stock Price, News & Analysis

$174.23
+1.78 (+1.03%)
(As of 03/27/2024 ET)
Today's Range
$172.14
$174.23
50-Day Range
$157.00
$176.00
52-Week Range
$143.46
$196.23
Volume
437 shs
Average Volume
514 shs
Market Capitalization
$22.52 billion
P/E Ratio
24.78
Dividend Yield
N/A
Price Target
N/A

Merck KGaA MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Merck KGaA in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.03%
From $9.34 to $10.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

MKGAF stock logo

About Merck KGaA Stock (OTCMKTS:MKGAF)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

MKGAF Stock Price History

MKGAF Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
MERCK KGAA DM 5 (OTC: MKGAF)
DGAP-DD: Merck KGaA english
See More Headlines
Receive MKGAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MKGAF
CIK
N/A
Employees
64,243
Year Founded
N/A

Profitability

Net Income
$3.06 billion
Pretax Margin
17.15%

Debt

Sales & Book Value

Annual Sales
$22.72 billion
Cash Flow
$52.32 per share
Book Value
$212.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$22.52 billion
Optionable
Not Optionable
Beta
0.93
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Belen Garijo Lopez M.D. (Age 64)
    Chair of Executive Board & CEO
    Comp: $7.19M
  • Ms. Helene von Roeder (Age 54)
    CFO & Member of Executive Board
    Comp: $1.34M
  • Dr. Kai Beckmann (Age 59)
    CEO of Electronics & Member of the Executive Board
    Comp: $5.27M
  • Mr. Peter Guenter (Age 62)
    CEO of Healthcare Business & Member of Executive Board
    Comp: $6.06M
  • Dr. Matthias J. Heinzel (Age 57)
    CEO of Life Science Sector & Member of Executive Board
    Comp: $5.67M
  • Ms. Barbara Weiland (Age 50)
    Chief Compliance Officer
  • Mr. Dietmar Eidens (Age 66)
    Head of the Global HR Business Partner Organization
  • Mr. Frank Gotthardt
    Head of Corporate & Government Relations - Europe
  • Mr. Marc Horn (Age 49)
    Head of Life Science Controlling
  • Dr. Michael Heckmeier (Age 57)
    Head of the Display Materials Business Unit for Performance Materials

MKGAF Stock Analysis - Frequently Asked Questions

How have MKGAF shares performed in 2024?

Merck KGaA's stock was trading at $161.00 on January 1st, 2024. Since then, MKGAF shares have increased by 8.2% and is now trading at $174.2250.
View the best growth stocks for 2024 here
.

How were Merck KGaA's earnings last quarter?

Merck KGaA (OTCMKTS:MKGAF) announced its quarterly earnings data on Thursday, March, 7th. The company reported $1.99 earnings per share for the quarter, missing analysts' consensus estimates of $2.15 by $0.16. The company had revenue of $5.63 billion for the quarter, compared to analysts' expectations of $5.58 billion. Merck KGaA had a trailing twelve-month return on equity of 12.14% and a net margin of 13.47%.

How do I buy shares of Merck KGaA?

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MKGAF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners